FGFR2 is one of four membrane‐bound receptor tyrosine kinases (RTKs) that mediate the signaling of over 22 fibroblast growth factors (FGFs).[6, 7] Multiple genetic aberrations in FGFR2 activate upstream and/or downstream FGFR2 signaling pathways and have been identified in breast cancer; 6 out of 165 (3.6%) triple‐negative breast cancers (TNBCs) bear the FGFR2 amplification 10q26.[8] Of the 51 screened breast cancer cell lines, MFM223 and SUM52PE manifested FGFR2 amplification and overexpression. The gene discussed is FGFR2; the disease is breast carcinoma.